Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary: A Prospective, Open-label, Single-arm Clinical Study

NCT05241132 is registered in ClinicalTrials.gov with Wei Xu as lead sponsor.

NCT NCT05241132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05241132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary: A Prospective, Open-label, Single-arm Clinical Study
Lead sponsor
Wei Xu
Phase
Phase 2
Overall status
Unknown status
Start date
November 12, 2021
Completion date
October 31, 2024
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone cancer metastatic, cancer of unknown primary, chemotherapy effect, gene mutation-related cancer, immune evasion, tumor, tislelizumab